Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Imago BioSciences, a clinical-stage biopharmaceutical company focused on treatments for myeloproliferative neoplasms, will participate in a Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 PM ET. CEO Hugh Young Rienhoff, Jr., MD, will represent the company during this analyst-led session.

The live webcast can be accessed on the company's Investor Relations website, with a replay available for 90 days post-event. Imago is currently evaluating its lead product candidate, Bomedemstat, in two Phase 2 clinical trials.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in an analyst led Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 pm Eastern Time / 10:10 am Pacific Time.

Interested parties can access the live webcast of the Fireside Chat by visiting the Investor Relations section of the company’s website at ir.imagobio.com. A webcast replay will be available after the conclusion of the event for approximately 90 days.

Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com

MEDIA
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

Source: Imago BioSciences

FAQ

What is Imago BioSciences planning for August 10, 2022?

Imago BioSciences will participate in a Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 PM ET.

Who will represent Imago BioSciences at the conference?

Hugh Young Rienhoff, Jr., MD, the CEO of Imago BioSciences, will participate in the Fireside Chat.

How can I access the Fireside Chat event for Imago BioSciences?

The live webcast can be accessed via the Investor Relations section of Imago BioSciences' website.

What clinical trials is Imago BioSciences currently conducting?

Imago BioSciences is evaluating its lead product candidate, Bomedemstat, in two Phase 2 clinical trials for treating essential thrombocythemia and myelofibrosis.

What designations has Bomedemstat received?

Bomedemstat has received U.S. FDA Orphan Drug and Fast Track Designation, as well as European Medicines Agency Orphan Designation for the treatment of essential thrombocythemia and myelofibrosis.